

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 517 916 157 US, in an envelope addressed to: MS Sequence, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: December 27, 2004

Signature: *Sharon Bizskas*

(Sharon Bizskas)

4
Docket No.: 61536(46342)
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Hirokazu Matsumoto et al.

Application No.: 10/500,175

Confirmation No.: 3286

Filed: June 25, 2004

Art Unit: N/A

For: BODY WEIGHT GAIN INHIBITOR

Examiner: Not Yet Assigned

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS
FOR PATENT APPLICATION CONTAINING NUCLEOTIDE
SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

MS Sequence
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

This is in response to the Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, dated October 27, 2004. Applicants are submitting their response herewith within the two-month response period set to expire on December 27, 2004.


The U.S. Patent and Trademark Office has taken the position that the previous "Sequence Listing" in computer readable form did not comply with the requirements of Section 1.824 for the stated reason that it contained several raw sequence listing errors. Submitted herewith in connection with the above-referenced patent application is a substitute, computer readable copy of the Sequence Listing that corrects the defects noted in the raw sequence listing. Also enclosed is a paper copy of the substitute Sequence Listing (36 pages, numbered 1-36), as well as a copy of the Notice. The contents of the computer readable copy and the paper copy of the substitute Sequence Listing are the same. No new matter has been added to the substitute Sequence Listing.

Applicants respectfully request the above-referenced patent application be entered in the application and placed upon the files for examination.

No fees are believed to be necessary in connection with the enclosed submission. However, should any fees be required, the Commissioner is hereby authorized to charge any fees, including any required extension fees, which may be required to consider this submission to Deposit Account No. **04-1105**.

Respectfully submitted,

By


Jennifer K. Rosenfield

Registration No.: 53,531

EDWARDS & ANGELL, LLP

P.O. Box 55874

Boston, Massachusetts 02205

(617) 439-4444

Agent for Applicant

Dated: December 27, 2004



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/500,175	Hirokazu Matsumoto	61536 (46342)

INTERNATIONAL APPLICATION NO.

PCT/JP02/13781

LA. FILING DATE	PRIORITY DATE
12/27/2002	12/28/2001

21874
 EDWARDS & ANGELL, LLP
 P.O. BOX 55874
 BOSTON, MA 02205

CONFIRMATION NO. 3286

371 FORMALITIES LETTER



OC000000014198815

Date Mailed: 10/27/2004

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

The following items **MUST** be furnished within the period set forth below:

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):
 - A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of Annex C of the Administrative Instructions and 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
 - APPLICANT MUST PROVIDE:
 - An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification.
 - A statement that the contents of the paper or compact disc and the computer readable form are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).
- For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:
 - For Rules Interpretation, call (703) 308-4216
 - To Purchase PatentIn Software, call (703) 306-2600
 - For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*


SHAKEEL AHMED

Telephone: (703) 305-3659

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/500,175	PCT/JP02/13781	61536 (46342)

FORM PCT/DO/EO/922 (371 Formalities Notice)



RAW SEQUENCE LISTING ERROR REPORT

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number: 10/500,175
Source: PG
Date Processed by STIC: 7/6/04

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.

PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION AND PATENTIN SOFTWARE QUESTIONS, PLEASE CONTACT MARK SPENCER, TELEPHONE: 571-272-2510; FAX: 571-273-0221

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE CHECKER VERSION 4.2 PROGRAM, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

<http://www.uspto.gov/web/offices/pac/checker/chkrnote.htm>

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.

Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

1. EFS-Bio (<<http://www.uspto.gov/efb/efs/downloads/documents.htm>> , EFS Submission User Manual - ePAVE)
2. U.S. Postal Service: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450
3. Hand Carry, Federal Express, United Parcel Service, or other delivery service (EFFECTIVE 06/05/04):
U.S. Patent and Trademark Office, 220 20th Street S., Customer Window, Mail Stop Sequence, Crystal Plaza Two, Lobby, Room 1B03, Arlington, VA 22202

Revised 05/17/04

Sequence Listing Error Summary

ERROR DETECTED

SUGGESTED CORRECTION

SERIAL NUMBER: 10/500,175

ATTN: NEW RULES CASES: PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE

- 1 Wrapped Nucleics
 Wrapped Aminos The number/text at the end of each line "wrapped" down to the next line. This may occur if your file was retrieved in a word processor after creating it. Please adjust your right margin to .3; this will prevent "wrapping."
- 2 Invalid Line Length The rules require that a line not exceed 72 characters in length. This includes white spaces.
- 3 Misaligned Amino
 Numbering The numbering under each 5th amino acid is misaligned. Do not use tab codes between numbers; use space characters, instead.
- 4 Non-ASCII The submitted file was not saved in ASCII(DOS) text, as required by the Sequence Rules. Please ensure your subsequent submission is saved in ASCII text.
- 5 Variable Length Sequence(s) contain n's or Xaa's representing more than one residue. Per Sequence Rules, each n or Xaa can only represent a single residue. Please present the maximum number of each residue having variable length and indicate in the <220>-<223> section that some may be missing.
- 6 PatentIn 2.0
 "bug" A "bug" in PatentIn version 2.0 has caused the <220>-<223> section to be missing from amino acid sequences(s) . Normally, PatentIn would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence. This applies to the mandatory <220>-<223> sections for Artificial or Unknown sequences.
- 7 Skipped Sequences
 (OLD RULES) Sequence(s) missing. If intentional, please insert the following lines for each skipped sequence
 (2) INFORMATION FOR SEQ ID NO: X: (insert SEQ ID NO where "X" is shown)
 (i) SEQUENCE CHARACTERISTICS: (Do not insert any subheadings under this heading)
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: X: (insert SEQ ID NO where "X" is shown)
 This sequence is intentionally skipped
 Please also adjust the "(ii) NUMBER OF SEQUENCES:" response to include the skipped sequences
- 8 Skipped Sequences
 (NEW RULES) Sequence(s) missing. If intentional, please insert the following lines for each skipped sequence
 <210> sequence id number
 <400> sequence id number
 000
- 9 Use of n's or Xaa's
 (NEW RULES) Use of n's and/or Xaa's have been detected in the Sequence Listing.
 Per 1.823 of Sequence Rules, use of <220>-<223> is MANDATORY if n's or Xaa's are present.
 In <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents.
- 10 Invalid <213>
 Response Per 1.823 of Sequence Rules, the only valid <213> responses are: Unknown, Artificial Sequence, or scientific name (Genus/species). <220>-<223> section is required when <213> response is Unknown or is Artificial Sequence
- 11 Use of <220> Use of <220> to <223> is MANDATORY if <213> "Organism" response is "Artificial Sequence" or "Unknown." Please explain source of genetic material in <220> to <223> section.
 (See "Federal Register," 00/01/1998, Vol. 63, No. 104, pp. 29631-32) (Sec. 1.823 of Sequence Rules)
- 12 PatentIn 2.0
 "bug" Please do not use "Copy to Disk" function of PatentIn version 2.0. This causes a corrupted file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing). Instead, please use "File Manager" or any other manual means to copy file to floppy disk.
- 13 Misuse of n/Xaa "n" can only represent a single nucleotide; "Xaa" can only represent a single amino acid



PCT

RAW SEQUENCE LISTING

DATE: 07/06/2004

PATENT APPLICATION: US/10/500,175

TIME: 12:17:47

Input Set : A:\61536 Sequence Listing.txt

Output Set: N:\CRF4\07062004\J500175.raw

3 <110> APPLICANT: Takeda Chemical Industries, Ltd.
 5 <120> TITLE OF INVENTION: Body weight gain inhibitor
 7 <130> FILE REFERENCE: P02-0149PCT
 C--> 9 <140> CURRENT APPLICATION NUMBER: US/10/500,175
 C--> 9 <141> CURRENT FILING DATE: 2004-06-25
 9 <150> PRIOR APPLICATION NUMBER: JP2001-403260
 10 <151> PRIOR FILING DATE: 2001-12-28
 12 <150> PRIOR APPLICATION NUMBER: JP2002-93096
 13 <151> PRIOR FILING DATE: 2002-03-28
 15 <160> NUMBER OF SEQ ID NOS: 150
 17 <210> SEQ ID NO: 1
 18 <211> LENGTH: 32
 19 <212> TYPE: DNA
 20 <213> ORGANISM: Artificial Sequence
 22 <220> FEATURE:
 23 <223> OTHER INFORMATION: Primer
 25 <400> SEQUENCE: 1
 26 atcgattaca atgcaggccg ctgggcaccc ag 32
 28 <210> SEQ ID NO: 2
 29 <211> LENGTH: 32
 30 <212> TYPE: DNA
 31 <213> ORGANISM: Artificial Sequence
 33 <220> FEATURE:
 34 <223> OTHER INFORMATION: Primer
 36 <400> SEQUENCE: 2
 37 actagtgccc ttcagcaccg caatatgctg cg 32
 39 <210> SEQ ID NO: 3
 40 <211> LENGTH: 1023
 41 <212> TYPE: DNA
 42 <213> ORGANISM: Human
 44 <400> SEQUENCE: 3
 45 atcgattaca atgcaggccg ctgggcaccc agagcccctt gacagcaggg gctccttctc 60
 46 cctccccacg atgggtgcc aagtctctca ggacaatggc actggccaca atgccacctt 120
 47 ctccgagcca ctgccgttcc tctatgtgct cctgcccgcc gtgtactccg ggatctgtgc 180
 48 tgtggggctg actggcaaca cggccgtcat ccttgtaatc ctaagggcgc ccaagatgaa 240
 49 gacggtgacc aacgtgttca tctgaacct ggccgtcgcc gacgggctct tcacgctggt 300
 50 actgcccgtc aacatcgccg agcacctgct gcagtactgg cccttcgggg agctgctctg 360
 51 caagctgggtg ctggccgtcg accactacaa catcttctcc agcatctact tcctagccgt 420
 52 gatgagcgtg gaccgatacc tgggtggtgct ggccaccgtg aggtcccgcc acatgccttg 480
 53 gcgcacctac cggggggcga aggtcgccag cctgtgtgtc tggctggggc tcacggctct 540
 54 ggttctgccc ttcttctctt tcgctggcgt ctacagcaac gagctgcagg tcccagctg 600
 55 tgggctgagc ttcccgtggc ccgagcaggt ctggttcaag gccagccgtg tctacacgtt 660
 56 ggtcctgggc ttctgtgctgc ccgtgtgcac catctgtgtg ctctacacag acctcctgcg 720

Does Not Comply
 Corrected Diskette Needed
 (p5.3, 4)

RAW SEQUENCE LISTING

DATE: 07/06/2004

PATENT APPLICATION: US/10/500,175

TIME: 12:17:47

Input Set : A:\61536 Sequence Listing.txt

Output Set: N:\CRF4\07062004\J500175.raw

```

57 caggctgctg gccgtgctgg tccgctctgg agccaaggct ctaggcaagg ccaggcgga 780
58 ggtgaccgtc ctggtcctcg tcgtgctggc cgtgtgcctc ctctgctgga cgcccttcca 840
59 cctggcctct gtcgtggccc tgaccacgga cctgccccag accccactgg tcatcagtat 900
60 gtctacgtc atcaccagcc tcagctacgc caactcgtgc ctgaaccctc tcctctacgc 960
61 ctttctagat gacaacttcc ggaagaactt ccgcagcata ttgcggtgct gaagggcact 1020
62 agt 1023
64 <210> SEQ ID NO: 4
65 <211> LENGTH: 333
66 <212> TYPE: PRT
67 <213> ORGANISM: Human
69 <400> SEQUENCE: 4
70 Met Gln Ala Ala Gly His Pro Glu Pro Leu Asp Ser Arg Gly Ser Phe
71 1 5 10 15
72 Ser Leu Pro Thr Met Gly Ala Asn Val Ser Gln Asp Asn Gly Thr Gly
73 20 25 30
74 His Asn Ala Thr Phe Ser Glu Pro Leu Pro Phe Leu Tyr Val Leu Leu
75 35 40 45
76 Pro Ala Val Tyr Ser Gly Ile Cys Ala Val Gly Leu Thr Gly Asn Thr
77 50 55 60
78 Ala Val Ile Leu Val Ile Leu Arg Ala Pro Lys Met Lys Thr Val Thr
79 65 70 75 80
80 Asn Val Phe Ile Leu Asn Leu Ala Val Ala Asp Gly Leu Phe Thr Leu
81 85 90 95
82 Val Leu Pro Val Asn Ile Ala Glu His Leu Leu Gln Tyr Trp Pro Phe
83 100 105 110
84 Gly Glu Leu Leu Cys Lys Leu Val Leu Ala Val Asp His Tyr Asn Ile
85 115 120 125
86 Phe Ser Ser Ile Tyr Phe Leu Ala Val Met Ser Val Asp Arg Tyr Leu
87 130 135 140
88 Val Val Leu Ala Thr Val Arg Ser Arg His Met Pro Trp Arg Thr Tyr
89 145 150 155 160
90 Arg Gly Ala Lys Val Ala Ser Leu Cys Val Trp Leu Gly Val Thr Val
91 165 170 175
92 Leu Val Leu Pro Phe Phe Ser Phe Ala Gly Val Tyr Ser Asn Glu Leu
93 180 185 190
94 Gln Val Pro Ser Cys Gly Leu Ser Phe Pro Trp Pro Glu Gln Val Trp
95 195 200 205
96 Phe Lys Ala Ser Arg Val Tyr Thr Leu Val Leu Gly Phe Val Leu Pro
97 210 215 220
98 Val Cys Thr Ile Cys Val Leu Tyr Thr Asp Leu Leu Arg Arg Leu Arg
99 225 230 235 240
100 Ala Val Arg Leu Arg Ser Gly Ala Lys Ala Leu Gly Lys Ala Arg Arg
101 245 250 255
102 Lys Val Thr Val Leu Val Leu Val Val Leu Ala Val Cys Leu Leu Cys
103 260 265 270
104 Trp Thr Pro Phe His Leu Ala Ser Val Val Ala Leu Thr Thr Asp Leu
105 275 280 285
106 Pro Gln Thr Pro Leu Val Ile Ser Met Ser Tyr Val Ile Thr Ser Leu
107 290 295 300

```


RAW SEQUENCE LISTING

DATE: 07/06/2004

PATENT APPLICATION: US/10/500,175

TIME: 12:17:47

Input Set : A:\61536 Sequence Listing.txt

Output Set: N:\CRF4\07062004\J500175.raw

```

108 Ser Tyr Ala Asn Ser Cys Leu Asn Pro Phe Leu Tyr Ala Phe Leu Asp
109 305                      310                      315                      320
110 Asp Asn Phe Arg Lys Asn Phe Arg Ser Ile Leu Arg Cys
111                      325                      330
113 <210> SEQ ID NO: 5
114 <211> LENGTH: 687
115 <212> TYPE: RNA
116 <213> ORGANISM: Artificial Sequence
118 <220> FEATURE:
119 <223> OTHER INFORMATION: Riboprobe
121 <400> SEQUENCE: 5
122 caaaagcugg agcuccaccg cgguggcggc cgcucuagcc cacuagugcc cuucagcacc 60
123 gcaauaugcu gcggaaguuc uuccggaagu ugucaucuag aaaggcguag aggaaggggu 120
124 ucaggcacga guuggcguag cugaggcugg ugaugacgua ggacauacug augaccagug 180
125 gggucugggg cagguccgug gucagggcca cgacagaggc cagguggaag ggcguccagc 240
126 agaggaggca cacggccagc acgacgagga ccaggacggu caccuuccgc cuggccuugc 300
127 cuagagccuu ggcuccagag cggagccgca cggcccgcag ccugcgcagg agguucugugu 360
128 agagcacaca gauggugcac acgggcagca cgaagcccag gaccaacgug uagacacggc 420
129 ugcccuugaa ccagaccugc ucgggccacg ggaagcucag cccacagcuu gggaccugca 480
130 gcucguugcu guagacgcca gcgaaagaga agaagggcag aaccaggacc gugacgcccc 540
131 gccagacaca caggcuggcg accuucgccc cccgguaggu gcgccagggc auguggcggg 600
132 accucacggu ggccagcacc accagguauc gguccacgcu caucacggcu aggaaguaga 660
133 ugcuggagaa gauguuguag uggucga 687
135 <210> SEQ ID NO: 6
136 <211> LENGTH: 17
137 <212> TYPE: PRT
138 <213> ORGANISM: Porcine
140 <400> SEQUENCE: 6
141 Trp Tyr Lys His Thr Ala Ser Pro Arg Tyr His Thr Val Gly Arg Ala
142 1                      5                      10                      15
143 Ala
145 <210> SEQ ID NO: 7
146 <211> LENGTH: 438
147 <212> TYPE: DNA
148 <213> ORGANISM: Human
150 <220> FEATURE:
W--> 151 <221> NAME/KEY:
152 <222> LOCATION: 408
153 <223> OTHER INFORMATION:
W--> 155 <400> 7
156 gccccatgag caggccagcg gcgcggccca ccgtgtggta gcggggactc gccacgtgct 60
157 tgtaccacgc gccggagggc agcggcagca ggagcagaag cagcagcagt gccagccgcg 120
158 gccggctcgc gggagcccc cgctcccctg gccgccacgc cagggcgctc gcgtcgacgg 180
159 ccgcccggcg gggcgggcca cgaaccggct cggctggggt tgggcgcgca gtggagttgg 240
160 gacgcccagg taccggagcg caggaggctg gaggcgagcc gtgggtcccc tgcaggccca 300
161 gctataaccg ctcggtggcc ccgcctcggt ccgccccctc agtaccgctg ggctccccag 360
W--> 162 atgggggggag ggacggaggg aggagagggg accctggcag ctggcggnng acgtgggtac 420
163 ttgagcacct cactgagt 438
165 <210> SEQ ID NO: 8

```

pls
explain
"N" location.

RAW SEQUENCE LISTING

DATE: 07/06/2004

PATENT APPLICATION: US/10/500,175

TIME: 12:17:47

Input Set : A:\61536 Sequence Listing.txt

Output Set: N:\CRF4\07062004\J500175.raw

```

166 <211> LENGTH: 264
167 <212> TYPE: DNA
168 <213> ORGANISM: Human
170 <400> SEQUENCE: 8
171 gataggggtga gcgacgcagc cccatgagca ggccagcggc gcggcccacc gtgtggtagc 60
172 ggggactcgc cacgtgcttg taccacgcgc cggagggcag cggcagcagg agcagaagca 120
173 gcagcagtgc cagccgcggc cggctcgcgg gagcccccg ctcccctggg cgccacgcca 180
174 gggcgctcgc gtcgacggcc gcccggcggg gcgggccacg aaccggctcg gctgggtttg 240
175 ggcgcgcagt ggagttggga cgcc 264
177 <210> SEQ ID NO: 9
178 <211> LENGTH: 424
179 <212> TYPE: DNA
180 <213> ORGANISM: Human
182 <400> SEQUENCE: 9
183 gataggggtga gcgacgcagc cccatgagca ggccagcggc gcggcccacc gtgtggtagc 60
184 ggggactcgc cacgtgcttg taccacgcgc cggagggcag cggcagcagg agcagaagca 120
185 gcagcagtgc cagccgcggc cggctcgcgg gagcccccg ctcccctggg cgccacgcca 180
186 gggcgctcgc gtcgacggcc gcccggcggg gcgggccacg aaccggctcg gctgggtttg 240
187 ggcgcgcagt ggagttggga cgcccaggta ccggagcgca ggaggctgga ggcgagccgt 300
188 ggggtcccctg caggcccagc tataaccgct cgggtggcccc gcctcgttcc gccccctcag 360
189 taccgctggg ctcccagat ggggggaggg acggaggagg gagagggaac cctggcagct 420
190 ggcg 424
192 <210> SEQ ID NO: 10
193 <211> LENGTH: 375
194 <212> TYPE: DNA
195 <213> ORGANISM: Human
197 <400> SEQUENCE: 10
198 ggcctcacc gtgtggtagc ggggactcgc cacgtgcttg taccacgcgc cggagggcagc 60
199 ggcacgagga gcagaagcag cagcagtgcc agccgcggcc ggctcgcggg agccccccgc 120
200 tcccctgggc gccacgcagg gctacagcgt cgacggccgc ccgcggggcc atcgcaaccg 180
201 gctcggctgg gtttgggcgc gcagtggagt tgggacgccc aggtaccgga gcgcaggagg 240
202 ctggaggcga gccgtgggtc ccctgcaggc ccagctataa ccgctcgggtg gccccgcctc 300
203 gttccgcccc ctacgtaccg ctgggctccc cagaatgggg gagggacgga gggaggagag 360
204 ggaaccctgg cagct 375
206 <210> SEQ ID NO: 11
207 <211> LENGTH: 260
208 <212> TYPE: DNA
209 <213> ORGANISM: Human
211 <220> FEATURE:
W--> 212 <221> NAME/KEY:
213 <222> LOCATION: 2, 61, 147, 189, 213, 237, 249
214 <223> OTHER INFORMATION:
W--> 216 <400> 11
W--> 217 gacgttctc ggggacataa accctgttct tgtcctaacc cgccaagggg ccatggactt 60
218 gagcgcgctg gcgtcgagca gagaagtacg gggccctggg ccggggctcc ggtgaaccgg 120
219 cccctgctac cgctactgct gcttctcctc ttgctacctc tgcccgccag cgctgggtac 180
220 aagcagctgg cgagccctcg ctatcacaca gtggctcgtg cctccgggct gctcatggg 240
221 ctgcgcctc cgtcctacct 260
223 <210> SEQ ID NO: 12

```

pls explain
"N" locations.

RAW SEQUENCE LISTING

DATE: 07/06/2004

PATENT APPLICATION: US/10/500,175

TIME: 12:17:47

Input Set : A:\61536 Sequence Listing.txt

Output Set: N:\CRF4\07062004\J500175.raw

```

224 <211> LENGTH: 24
225 <212> TYPE: DNA
226 <213> ORGANISM: Artificial Sequence
228 <220> FEATURE:
229 <223> OTHER INFORMATION: Primer
231 <400> SEQUENCE: 12
232 aactccactg cgcgcccaaa ccca 24
234 <210> SEQ ID NO: 13
235 <211> LENGTH: 24
236 <212> TYPE: DNA
237 <213> ORGANISM: Artificial Sequence
239 <220> FEATURE:
240 <223> OTHER INFORMATION: Primer
242 <400> SEQUENCE: 13
243 tctcccacag ctctgaacc cacg 24
245 <210> SEQ ID NO: 14
246 <211> LENGTH: 375
247 <212> TYPE: DNA
248 <213> ORGANISM: Human
250 <400> SEQUENCE: 14
251 aactccactg cgcgcccaaa cccagccgag ccggttcgtg gcccgccccg ccgggcgggc 60
252 gtcgacgcga gcgccctggc gtggcgccca ggggagcggg gggctcccgc gagccggccg 120
253 cggttgacac tgctgctgct tctgctcctg ctgccgctgc cctccggcgc gtggtacaag 180
254 cacgtggcga gtccccgcta ccacacggtg ggccgcgccg ctggcctgct catggggctg 240
255 cgtcgctcac cctatctgtg gcgccgcgcg ctgcgcgcgg ccgccgggpc cctggccagg 300
256 gacaccctct ccccggaacc cgcagcccg caggctcctc tctgctgcc ctctggggtt 360
257 caggagctgt gggag 375
259 <210> SEQ ID NO: 15
260 <211> LENGTH: 125
261 <212> TYPE: PRT
262 <213> ORGANISM: Human
264 <400> SEQUENCE: 15
265 Asn Ser Thr Ala Arg Pro Asn Pro Ala Glu Pro Val Arg Gly Pro Pro
266 1 5 10 15
267 Arg Arg Ala Ala Val Asp Ala Ser Ala Leu Ala Trp Arg Pro Gly Glu
268 20 25 30
269 Arg Gly Ala Pro Ala Ser Arg Pro Arg Leu Ala Leu Leu Leu Leu
270 35 40 45
271 Leu Leu Leu Pro Leu Pro Ser Gly Ala Trp Tyr Lys His Val Ala Ser
272 50 55 60
273 Pro Arg Tyr His Thr Val Gly Arg Ala Ala Gly Leu Leu Met Gly Leu
274 65 70 75 80
275 Arg Arg Ser Pro Tyr Leu Trp Arg Arg Ala Leu Arg Ala Ala Gly
276 85 90 95
277 Pro Leu Ala Arg Asp Thr Leu Ser Pro Glu Pro Ala Ala Arg Glu Ala
278 100 105 110
279 Pro Leu Leu Leu Pro Ser Trp Val Gln Glu Leu Trp Glu
280 115 120 125
282 <210> SEQ ID NO: 16

```

RAW SEQUENCE LISTING ERROR SUMMARY
PATENT APPLICATION: US/10/500,175

DATE: 07/06/2004
TIME: 12:17:48

Input Set : A:\61536 Sequence Listing.txt
Output Set: N:\CRF4\07062004\J500175.raw

Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

Seq#:7; N Pos. 408 ✓
Seq#:11; N Pos. 2, 61, 147, 189, 213, 237, 249
Seq#:95; Xaa Pos. 21
Seq#:103; Xaa Pos. 21
Seq#:104; Xaa Pos. 21
Seq#:105; Xaa Pos. 1
Seq#:106; Xaa Pos. 1
Seq#:111; Xaa Pos. 1
Seq#:112; Xaa Pos. 1
Seq#:113; Xaa Pos. 1

<210> 103
 <211> 23
 <212> PRT
 <213> Artificial Sequence

pls explain

← mandatory, if

<220>

<221>

<222> 21

<223> Xaa on the 21st position means Met(O)

summary
sheet.

<213> response is
artificial/Unkna

<400> 103

Trp Tyr Lys His Thr Ala Ser Pro Arg Tyr His Thr Val Gly Arg Ala
 1 5 10 15

Ala Gly Leu Leu Xaa Gly Leu
 20

please explain,
 in section
 <220> -
 <223>.

The type of errors shown exist throughout
 the Sequence Listing. Please check subsequent
 sequences for similar errors.

VERIFICATION SUMMARY

PATENT APPLICATION: US/10/500,175

DATE: 07/06/2004

TIME: 12:17:48

Input Set : A:\61536 Sequence Listing.txt

Output Set: N:\CRF4\07062004\J500175.raw

L:9 M:270 C: Current Application Number differs, Replaced Current Application No
L:9 M:271 C: Current Filing Date differs, Replaced Current Filing Date
L:151 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:7 ✓
L:155 M:258 W: Mandatory Feature missing, <223> Blank for SEQ#:7,Line#:153 ✓
L:162 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:7 after pos.:360
L:212 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:11 ✓
L:216 M:258 W: Mandatory Feature missing, <223> Blank for SEQ#:11,Line#:214
L:217 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:11 after pos.:0
M:341 Repeated in SeqNo=11
L:1289 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:95 ✓
L:1296 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:95 after pos.:16
L:1377 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:103
L:1384 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:103 after pos.:16
L:1393 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:104 ✓
L:1400 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:104 after pos.:16
L:1409 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:105
L:1414 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:105 after pos.:0
L:1425 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:106
L:1430 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:106 after pos.:0
L:1481 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:111
L:1486 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:111 after pos.:0
L:1497 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:112 ✓
L:1502 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:112 after pos.:0
L:1513 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:113
L:1518 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:113 after pos.:0 ✓
L:2069 M:258 W: Mandatory Feature missing, <223> Blank for SEQ#:150,Line#:2067



DT07 Rec'd PCT/PTO 27 DEC 2004

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/500,175-Conf. #3286
	Filing Date	June 25, 2004
	First Named Inventor	Hirokazu Matsumoto
	Art Unit	N/A
	Examiner Name	Not Yet Assigned
Total Number of Pages in This Submission	Attorney Docket Number	61536(46342)

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please Identify below): Sequence Listing Paper Copy (36 pages); Sequence Listing Diskette, Sequence Statement (1 page); and Copy of Notification to Comply with Requirements.
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	EDWARDS & ANGELL, LLP		
Signature			
Printed name	Jennifer K. Rosenfield		
Date	December 27, 2004	Reg. No.	53,531

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 517 916 157 US, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: December 27, 2004

Signature: (Sharon Bizokas)